Erasca’s shares slid 53% after the company disclosed a patient death during ERAS-0015 development, according to StockWatch reporting. The oral pan-RAS molecular glue reported unconfirmed overall response rates in KRAS G12X NSCLC and PDAC cohorts, but a 66-year-old patient died after pneumonitis progressed to a grade 5 event. Erasca said the patient, with heavily pretreated metastatic pancreatic cancer and pulmonary metastases, had grade 3 pneumonitis treated with discontinuation, high-dose steroids, and infliximab; the patient later requested withdrawal of supportive care. Company leadership characterized the death as a rare event, but the disclosure is now likely to intensify scrutiny of pulmonary toxicity risk management. For investors and clinicians, the near-term issue is how Erasca updates monitoring, supportive care protocols, and future dosing parameters—especially in pancreatic cancer, where the unmet need is high and historical outcomes remain poor.